The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
Also known as: Iron and TIBC, Iron and Total Iron Binding Capacity TIBC, TIBC
Also known as: Lipid Panel with Ratios (fasting), Lipid Profile with Ratios (fasting), Lipids
Also known as: Reverse T3, Reverse Triiodothyronine, RT3, T3 Reverse RT3 LCMSMS, Triiodothyronine Reverse
Also known as: Triiodothyronine
Also known as: Free T3, FT3, T3 Free
Also known as: T4 Thyroxine Total
Also known as: Free T4, FT4, T4 Free
Also known as: Thyroid Stimulating Hormone, Thyroid Stimulating Hormone (TSH), Thyrotropin
Also known as: B12, B12 Vitamin, Cobalamin, Cyanocobalamin, Vitamin B12 Cobalamin
The TH-2. Graves Disease panel contains 13 tests with 78 biomarkers.
Brief Description: The TH-2 Graves' Disease panel is an advanced diagnostic array specifically tailored for the comprehensive evaluation of Graves' disease, an autoimmune disorder that often leads to hyperthyroidism. This panel encompasses a wide range of tests that assess not only thyroid function but also potential systemic impacts and related health concerns.
Collection Method: Blood Draw
Specimen Type: Whole Blood and Serum
Test Preparation: Patient should be fasting 9-12 hours prior to collection.
Collection should be done in the morning.
Specifc to TSH: Specimen collection after fluorescein dye angiography should be delayed for at least 3 days. For patients on hemodialysis, specimen collection should be delayed for 2 weeks.
According to the assay manufacturer Siemens: "Samples containing fluorescein can produce falsely depressed values when tested with the Advia Centaur TSH3 Ultra assay."
Healthcare professionals may order the TH-2 Graves' Disease panel for individuals exhibiting symptoms of hyperthyroidism, such as rapid heartbeat, weight loss, increased appetite, and anxiety, which are indicative of Graves' disease. It is also valuable for monitoring the disease's progression and the effectiveness of treatments, as well as evaluating the overall health status and potential complications related to Graves' disease.
While the TH-2 panel provides a comprehensive overview, the TH-3 and TH-4 Graves' Disease panels offer deeper insights, particularly into the autoimmune nature and more complex aspects of the disease.
TH-3 Graves' Disease Panel: Expands upon TH-2 by including thyroid antibody tests (Thyroid Peroxidase Antibodies and Thyroglobulin Antibodies), which are crucial for confirming the autoimmune basis of Graves' disease. The addition of Vitamin B6 enriches the panel's capability to assess neurological health and metabolic function.
TH-4 Graves' Disease Panel: The most exhaustive panel, TH-4 incorporates all tests from TH-3 and adds TSH Receptor Binding Antibody and Thyroid Stimulating Immunoglobulin tests, specific markers for Graves' disease, providing comprehensive insights into the disease's pathophysiology and guiding more targeted treatment strategies.
The TH-2 Graves' Disease panel is adept at diagnosing Graves' disease through elevated thyroid hormone levels and suppressed TSH. It also helps identify and manage potential complications such as osteoporosis, cardiovascular diseases, and diabetes, which can be exacerbated by hyperthyroidism.
Healthcare professionals utilize the TH-2 panel results to diagnose Graves' disease, assess the severity of hyperthyroidism, and evaluate the body's overall health and metabolic status. The comprehensive nature of the panel allows for the identification and management of complications, ensuring a holistic approach to patient care.
The TH-2 Graves' Disease panel stands as a pivotal tool in diagnosing and managing Graves' disease, offering a broad perspective on thyroid function and its systemic effects. By incorporating a wide array of metabolic, nutritional, and hormonal assessments, this panel enables healthcare providers to craft a nuanced treatment plan, addressing the complexities of Graves' disease and its associated health risks. For those requiring further investigation into the autoimmune aspects or more complex manifestations of Graves' disease, the TH-3 and TH-4 panels provide additional layers of diagnostic detail.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.